Fitusiran sodium

• CAT Number: I040052
• Molecular Formula: C520H635F21N175Na44O309P43S6
• Molecular Weight: 17215.34
• Purity: ≥95%

Fitusiran sodium (Cat No.: I040052) is an investigational RNA interference (RNAi) therapeutic targeting antithrombin (AT), developed for treating hemophilia A and B, with or without inhibitors. It works by reducing antithrombin levels in the liver, thereby enhancing thrombin generation and promoting blood clotting. Administered subcutaneously, fitusiran offers a potential prophylactic option with monthly dosing. By rebalancing hemostasis rather than replacing missing clotting factors, it represents a novel therapeutic strategy. Fitusiran sodium is being evaluated in clinical trials for safety and efficacy in bleeding disorder management.

Reference

[1]. Pasi KJ, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436-1446.
[Content Brief]